| |
HEALTH POLICY |
|
Healthcare Reimbursement Studies |
|
PHP1 |
ASSESSMENT OF PROPOSED GUIDELINES FOR PHARMACOECONOMIC
SUBMISSIONS IN GREECE: OVERVIEW AND IMPLEMENTATION PROBLEMS
Geitona M1, Karokis A2, Vandoros C3, Karamalis M4, 1National
School of Public Health, Athens, Greece; 2AstraZeneca SA, Maroussi,
Greece; 3Janssen-Cilag Pharmaceutical S.A.C.I, Pefki, Greece; 4Novo
Nordisk A/S, Vouliagmeni, Greece |
|
PHP2 |
VARIABILITY IN EUROPEAN REIMBURSEMENT SCHEMES FOR
ANTIBIOTICS: CONSEQUENCES FOR EUROPEAN SURVEILLANCE OF ANTIBIOTIC
CONSUMPTION (ESAC PROJECT)
Ferech M, Elseviers MM, Vander Stichele RH, Goossens H,
University of Antwerp, Wilrijk-Antwerp, Belgium |
|
PHP3 |
IMPROVING PATIENT ACCESS TO INNOVATION - THE NEW
BELGIAN REIMBURSEMENT PROCEDURE
Umbach I, Quaetaert M, Vannecke C, Dewitte M, Ravelingien
I, Verpooten G, Tomas M, NIHISB, Brussels, Belgium |
|
PHP4 |
OUT-OF-POCKET PAYMENT IN BELGIUM: AN ANALYSIS IN
RELATION TO PATHOLOGY
Ooms D, Puttevils D, Wissels G, Koen P, Dirk C, Beeckmans J, Free
University Brussels, Brussels, Belgium |
|
PHP5 |
“AUT IDEM” – 250 MILLION € SAVINGS P. A. FOR
STATUARY HEALTH INSURANCE IN GERMANY?
Pirk O, Rosenfeld S, Hass B, Fricke FU
Fricke & Pirk GmbH, Nuremberg, Germany |
|
PHP6 |
DRUG COSTS REGULATION SYSTEM IN THE SLOVAK
REPUBLIC
Tomek D
Health Insurance Fund APOLLO, Bratislava, Slovak Republic |
|
Healthcare Management/Practice
Guidelines/Prescribing Studies |
|
PHP7 |
MODELLING, ECONOMIC EVALUATIONS AND THE
DEVELOPMENT OF CLINICAL PRACTICE GUIDELINES: A SURVEY OF 38 GUIDELINES
IN THE NETHERLANDS
Redekop WK1, Niessen LW1, de Laet C1, Kok E1, Grijseels E1, Koopmanschap
M2, Rutten FFH2
1Erasmus Medical Center, Rotterdam, Netherlands; 2Erasmus University,
Rotterdam, Netherlands |
|
PHP8 |
AN ECONOMIC MODEL FOR COOPERATION BETWEEN A
NOT-FOR-PROFIT HMO AND A PHARMACEUTICAL COMPANY IN A DISEASE MANAGEMENT
PROGRAM: TRANSFORMING CONFLICT OF INTERESTS INTO UTILITY MAXIMIZATION
Shavit O1, Raz M2, Chen M3, Blay A3, Friedman N2, Hoffman A1
1Hebrew University of Jerusalem, Jerusalem, Israel; 2Maccabi Healthcare
Services, Tel-Aviv, Israel; 3Teva Pharmaceutical Industries, Netanya,
Israel |
|
PHP9 |
RISK SHARING IN A STATE FUNDED HEALTH SERVICE:
OUTCOMES GUARANTEE PROJECT
Chapman SR, Reeve E
Keele University, Newcastle under Lyme, Staffordshire, United Kingdom
|
|
PHP10 |
WITHDRAWN |
|
PHP11 |
DESCRIPTIVE AND COMPARATIVE STUDY OF
PATIENT-MANAGEMENT BY HOMEOPATHIC GPS VERSUS ALLOPATHIC GPS
Vainchtock A1, Lamarsalle L1, Trichard M2, Chaufferin G2, Nicoloyannis
N3
1GYD Institut, Lyon, France; 2Laboratoires Boiron, Sainte-Foy-Lčs-Lyon,
France; 3Université Lumičre Lyon 2, Bron, France |
|
PHP12 |
SELF-REPORTED PATIENT EXPERIENCE DATA, PROVIDED TO
PHYSICIANS AT THE POINT-OF-CARE, OFFERS AN IMPORTANT COMPLEMENT TO
TRADITIONAL EFFICACY DATA AND ENABLES THE DERIVATION OF PRACTICE-WIDE
TREATMENT GUIDELINES
Schmeichel CJ, Netherton DR,
InfoMedics, Inc, Woburn, MA, USA |
|
PHP13 |
INFLUENCING PRESCRIBING IN ENGLISH PRIMARY CARE:
FINDINGS FROM THE MANMED SURVEY
Mason A1, Drummond M1, Towse A2, Cooke J3
1University of York, York, United Kingdom; 2Office of Health Economics,
London, United Kingdom; 3South Manchester University Hospitals NHS
Trust, Manchester, United Kingdom |
|
PHP14 |
MANAGING THERAPEUTICS
NOVELTIES USING A SCIENTIFIC EVIDENCE-BASED METHOD
Catalan A, Perez MT, Gene J
Catalonian Health Institute, Barcelona, Spain |
|
Healthcare Expenditure Studies |
|
PHP15 |
THE USE OF
PATHOLOGY-RELATED PARAMETERS IN EXPLAINING THE VARIATION OF PUBLIC
EXPENDITURES ON MEDICAL IMAGING
Puttevils D, Ooms D, Wissels G, Putman K, Corens D, Beeckmans J
Free University Brussels, Brussels, Belgium |
|
PHP16 |
GENERIC DRUG PRICES
ARE TYPICALLY HIGHER IN CANADA THAN IN THE UNITED STATES
Palmer WN, D'Angelo J
Palmer D'Angelo Consulting Inc, Ottawa, ON, Canada |
|
PHP17 |
SPANISH NATIONAL
HEALTH SERVICE (NHS): PHARMACEUTICAL CONSUMPTION AND ESTIMATION OF THE
SAVING WITH GENERIC DRUG PRESCRIPTIONS
Gaspar D, Marińo E
University of Barcelona, Barcelona, Spain |
|
PHP18 |
ESTIMATING THE
ECONOMIC BURDEN OF HOSPITALIZATION DUE TO PATIENT NONADHERENCE IN CANADA
Iskedjian M1, Addis A2, Einarson T3
1Pharmideas Research and Consulting Inc, Oakville, ON, Canada; 2Centro
per la Valutazione della Efficacia della Assistenza Sanitaria, Modena,
Italy; 3University of Toronto, Toronto, ON, Canada |
|
PHP19 |
HEALTH EXPENDITURE FOR
THE DURATION OF LAST YEAR OF LIFE IN TAIWAN
Liang LY, Lan CF
National Yang-Ming University, Taipei, Taiwan |
|
PHP20 |
HARMONIZATION OF
HOSPITAL COSTS
Jacobs P1, Finlayson G2, Rapoport J3
1University of Alberta, Edmonton, AB, Canada; 2Manitoba Centre for
Health Policy, Oak Park, IL, USA; 3Mount Holyoke College, South Hadley,
MA, USA |
|
Healthcare Information Studies |
|
PHP21 |
WITHDRAWN |
|
PHP22 |
WEBSITES AS TOOLS OF
PROMOTING HEALTH IN SOUTH EAST EUROPE
Tasic Lj, Miljkovic B, Velickovic R
University of Belgrade, Faculty of Pharmacy, Belgrade, Yugoslavia |
|
Healthcare Study Methodology Issues |
|
PHP23 |
THE CONTRIBUTION OF
HEALTH ECONOMICS TO PORTFOLIO MANAGEMENT DECISIONS: A VACCINE INDUSTRY
EXAMPLE
Staginnus U
Baxter, Madrid, Spain |
|
PHP24 |
USE OF POLICY MODELING
TO PROMOTE INFORMED DECISION MAKING: DEVELOPMENT AND APPLICATION OF THE
CANADIAN STROKE POLICY MODEL
Matchar DB1, Samsa GP1, Nichol G2, Peters KP1, Shurr E1, Engelhart L1,
Bushnell CD1
1Duke University, Durham, NC, USA; 2University of Ottawa, Ottawa, ON,
Canada |
|
PHP25 |
METHODOLOGICAL ISSUES:
RESOURCE-BASED ZERO WORK HOUR PROCEDURES IN U.S. PHYSICIANS' OFFICES
Baker JJ
University of Rochester, Pickton, TX, USA |
|
PHP26 |
CLASSIFICATION AND
REGRESSION TREES HELP IN DEVELOPING EMBEDDED EVIDENCE- AND
CONSENSUS-BASED GUIDELINES
Marchetti M1, Barosi G1, Tura S2
1IRCCS Policlinico S. Matteo, Pavia, Italy; 2Policlinico S'Orsola,
Bologna, Italy |
|
PHP27 |
HEALTH STATE
VALUATIONS IN SUMMARY MEASURES OF POPULATION HEALTH
Salomon J, Murray CJ, Ustun B, Chatterji S
World Health Organization, Geneva, Switzerland |
|
PHP28 |
ECONOMIC STUDY OF
MALNUTRITION IN ELDERLY PATIENTS LIVING IN THE COMMUNITY: USE OF
PROPENSITY SCORE TO ANALYZE OBSERVATIONAL DATA
Schmitt C1, Aussage P1, Arnaud-Battandier F2
1MDS Pharma Services, Sevres, France; 2Nestlé Clinical Nutrition,
Noisiel, France |
|
PHP29 |
HEALTH CARE REFORMS IN RUSSIA
Piquard Y, Späth H,
University of Lyon, Lyon, France |
| |
ARTHRITIS/OSTEOPOROSIS |
|
Economic Outcomes Presentations |
|
PAR1 |
PHARMACOECONOMIC
ANALISIS OF THE TREATMENT WITH LEFLUNOMIDE-METHOTREXATE OR
INFLIXIMAB-METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT
TO METHOTREXATE
Rubio Terrés C1, Romero F1, Burrell A2, Domínguez-Gil A3
1Aventis Pharma S.A, Madrid, Spain; 2Aventis, Bridgewater, NJ, USA;
3Hospital Universitario, Salamanca, Spain |
|
PAR2 |
THE COST-EFFECTIVENESS
ANALYSIS OF CELECOXIB AND NSAIDS WITH GASTROPROTECTIVE AGENTS FOR
TREATMENT OF RHEUMATOID ARTHRITIS IN UKRAINE
Zaliska O
Lviv Medical University, Lviv, Ukraine |
|
PAR3 |
VARIATION IN RESOURCE
UTILIZATION AND TREATMENT COSTS FOR RHEUMATOID ARTHRITIS (RA) ACROSS 5
COUNTRIES IN AN ADALIMUMAB (D2E7) CLINICAL TRIAL
Van de Putte L1, Bergemann R2, Rosery H2, Pang F3, Dietz B4, Kupper H4,
Ashraf T5
1University Hospital Nijmegen, Nijmegen, Netherlands; 2Institute for
Medical Outcome Research, Lorrach, Germany; 3Abbott Laboratories UK Ltd,
Maidenhead, Berkshire, United Kingdom; 4Abbott GmbH & Co. KG,
Ludwigshafen, Germany; 5Abbott Laboratories, Chicago, IL, USA |
|
PAR4 |
WITHDRAWN |
|
PAR5 |
DISEASE SEVERITY AND
COSTS AMONG PATIENTS STARTING A TREATMENT WITH COX-2 SPECIFIC INHIBITORS
VERSUS NSAIDS PATIENTS IN ITALY: QUANTITATIVE ASSESSMENT IN 442 PATIENTS
WITH ARTHRITIS
Lucioni C1, Chinellato A2, Mazzi S1, Roggeri D3, Chiroli S3
1ADIS International, Milano, Italy; 2Servizio Farmaceutico Territoriale,
Treviso, Italy; 3Pharmacia Italia SpA, Milano, Italy |
|
PAR6 |
ANALYSIS OF
CONSUMPTION OF NON-STEROID ANTIINFLAMMATORY DRUGS (GROUP M01) AT
NATIONAL LEVEL IN DDD/1000/DAY: 1999-2001
Borissov BN, Popova MJ, Kulaksazova RA
Bulgarian Drug Agency, Sofia, Bulgaria |
|
PAR7 |
MODELLED
COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF VARIOUS TREATMENT
STRATEGIES IN OSTEOPOROTIC POSTMENOPAUSAL WOMEN IN POLAND
Orlewska E1, Lis J2
1Medical University of Warsaw, Warsaw, Poland; 2Eli Lilly Polska,
Warsaw, Poland |
| |
CARDIOVASCULAR
DISEASES/DISORDERS (Including Smoking, Obesity, & Stroke) |
|
Economic Outcomes Presentations |
|
PCV1 |
AN ECONOMIC EVALUATION
OF CLOPIDOGREL IN SECONDARY PREVENTION OF ISCHEMIC EVENTS: HIGH RISK
POPULATIONS
Levy E1, Gabriel S2, Carita P2, Dinet J2
1Mediconomie, Paris, France; 2Sanofi-Synthelabo, Bagneux, France |
|
PCV2 |
PHYSICIAN
CHARACTERISTICS OF THE NAVIGATOR TRIAL PREDICT AVERAGE LENGTH OF STAY (ALOS)
IN ACUTE CORONARY SYNDROME (ACS)
Friedman JY1, Curtis L1, Gnanasakthy A2, Schulman KA1
1Duke Clinical Research Institute, Durham, NC, USA; 2Novartis
Pharmaceuticals, East Hanover, NJ, USA |
|
PCV3 |
WITHDRAWN |
|
PCV4 |
COST-EFFECTIVENESS
ANALYSIS OF N-3 POLYUNSATURED FATTY ACIDS (PUFA) AFTER MYOCARDIAL
INFARCTION, FRENCH ASSESSMENT
Taďeb C1, Abbadie S2, Myon E1
1Programmes Pharmaco Economiques Pierre Fabre, Boulogne Billancourt,
France; 2Affaires économiques Pierre Fabre, Boulogne Billancourt, France
|
|
PCV5 |
COST IMPACT OF
AMLODIPINE IN BRITISH COLUMBIA BASED ON THE PREVENT TRIAL RESULTS
Ali F1, McKenzie E2, Bruchet R1
1Pfizer Canada Inc, Kirkland, QC, Canada; 2Applied Management, Toronto,
ON, Canada |
|
PCV6 |
THE COST COMPARISON OF
CARDIOVERSION AND ANTIARRHYTHMIC THERAPY IN NONVALVULAR CHRONIC ATRIAL
FIBRILLATION
Pietrasik AL1, Latek MM2, Niewada MP1, Kamiński B2, Kosior D1
1Medical University of Warsaw, Warsaw, Poland; 2Warsaw School of
Economics, Warsaw, Poland |
|
PCV7 |
ECONOMIC EVALUATION OF
THE ATORVASTATIN VERSUS REVASCULARIZATION TREATMENT STUDY (AVERT): AN
ITALIAN CUSTOMIZATION
Ruffo P1, Campanella S2, Bustacchini S1, Mantovani LG2
1Pfizer Italia S.r.l, Rome, Italy; 2Universita' degli Studi di Milano,
Milan, Italy |
|
PCV8 |
ECONOMIC EVALUATION OF
THE CORONARY ANGIOPLASTY AMLODIPINE RESTENOSIS STUDY (CAPARES): AN
ITALIAN CUSTOMIZATION
Bustacchini S1, Rossetti F2, Ruffo P1, Mantovani LG2
1Pfizer Italia S.r.l, Rome, Italy; 2Universita’ degli Studi di Milano,
Milan, Italy |
|
PCV9 |
OUTCOMES AND COSTS OF
THROMBOPROPHYLAXIS WITH LOW-MOLECULAR WEIGHT HEPARIN IN ACUTELY-ILL
MEDICAL INPATIENTS
Thompson D, McGarry L
Innovus Research, Inc, Medford, MA, USA |
|
PCV10 |
COST OF UNCONTROLLED
HYPERTENSION IN CANADA
Ali F1, Scott DA2, Lloyd A2, Feldman RD3
1Pfizer Canada Inc, Kirkland, QC, Canada; 2Fourth Hurdle Consulting,
London, United Kingdom; 3Robarts Research Institute, London, ON, Canada
|
|
PCV11 |
RESOURCE UTILIZATION
DURING THE FOUR MONTHS FOLLOWING A DIAGNOSIS OF DEEP VENOUS
THROMBOSIS
Kahn SR1, Ducruet T1, Johri M2, Arsenault L1, Venous Thrombosis Outcomes
(VETO) Study Investigators3
1McGill University, Montreal, QC, Canada; 2Université de Montréal,
Montreal, QC, Canada; 3McGill University, Université de Montréal,
Université de Laval, Montreal, QC, Canada |
|
PCV12 |
COST-EFFECTIVENES OF
ENOXAPARIN AS THROMBOPROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS IN
BRAZIL
Nuijten MJC1, Mussi N2, Kosa J1, Ramacciotti E1, Glancspiegel D1,
Nadipelli V2
1MEDTAP International, Jisp, Netherlands; 2Aventis Pharmaceuticals, Inc,
Bridgewater, NJ, USA |
|
PCV13 |
COST OF MANAGING
UNSTABLE ANGINA PATIENTS OVER A NINE-MONTH PERIOD: A EUROPEAN APPROACH
Gabriel S, Spiesser J, Jourdan S, Carita P
Sanofi-Synthelabo, Bagneux, France |
|
PCV14 |
ECONOMIC EVALUATION OF
A COMPLIANCE PROGRAM IN PATIENTS WITH STATIN THERAPY – DESIGN AND PILOT
PHASE OF THE ORBITAL STUDY
Upmeier H1, Müller-Nordhorn J1, Sonntag F2, Voeller H3, Wegscheider K4,
Windler E5, Meyer-Sabellek W6, Katus HA7, Willich SN1
1Institute of Social Medicine, Epidemiology and Health Economics,
Charité Hospital, Humboldt University of Berlin, Berlin, Germany; 2Cardiologist,
Henstedt-Ulzburg, Germany; 3Rehabilitation Center for Cardiovascular
Diseases, Rüdersdorf, Germany; 4University of Hamburg, Berlin, Germany;
5University Hospital Hamburg-Eppendorf, Hamburg, Germany; 6AstraZeneca
GmbH, Wedel, Germany; 7Medizinische Universität zu Lübeck, Lübeck,
Germany |
|
PCV15 |
MANAGEMENT
EFFECTIVENESS AND COST/UTILITY RATIO IN CHRONIC HEART FAILURE:
COMPARISON BETWEEN HEART FAILURE MANAGEMENT PROGRAM DELIVERED BY
DAY-HOSPITAL AND USUAL CARE
Capomolla S, Ceresa M, Febo O, Guazzotti G, Caporotondi A, Ferrari M,
Lenta F, Pinna G, Maestri R, Cobelli F
Fondazione "S. Maugeri" IRCCS Pavia, Montescano, Pavia, Italy |
|
PCV16 |
INCIDENCE AND ECONOMIC
BURDEN OF DEEP VEIN THROMBOSIS AFTER TOTAL HIP REPLACEMENT IN HONG KONG
Lee KK, Tang P, Chan S, Liu P, Cheung K, Leung K
The Chinese University of Hong Kong, Hong Kong, China |
|
PCV17 |
COST-EFFECTIVENESS
ANALYSIS OF TREATMENTS TO REDUCE CHOLESTEROL CONCENTRATION, BLOOD
PRESSURE AND SMOKING FOR THE PREVENTION OF CORONARY HEART DISEASE
Plans-Rubió P
Departament de Sanitat of Catalonia SCS, Barcelona, Spain |
|
PCV18 |
SOCIOECONOMIC
RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH
CRATAEGUS EXTRACT WS® 1442 – TWO-YEAR-RESULTS OF A PROSPECTIVE
PHARMACOECONOMIC STUDY
Rychlik R1, Pfeil T1, Daniel D1, Habs M2, Klapper HG2
1Institute of Empirical Health Economics, Burscheid, Germany; 2Dr.
Willmar Schwabe Arzneimittel, Karlsruhe, Germany |
|
PCV19 |
TWO METHODS OF
ASSESSING COSTS OF PHARMACOLOGICAL TREATMENT ASSOCIATED WITH CHRONIC
VENOUS INSUFFICIENCY (CVI) IN POLAND
Czech M, Faluta T, Pachocki R
Servier Polska, Warsaw, Poland |
|
PCV20 |
A COST EFFECTIVENESS
ANALYSIS OF SPIRONOLACTONE IN THE MANAGEMENT OF PATIENTS WITH SEVERE
CHRONIC HEART FAILURE (CHF) IN THE IRISH HEALTHCARE SETTING
Tilson L1, McGowan B1, Barry M2, Ryan M2
1National Centre for Pharmacoeconomics, Dublin, Ireland; 2National
Centre for Pharmacoeconomics, James's St, Ireland |
|
PCV21 |
ECONOMIC EVALUATION OF
THE PROSPECTIVE RANDOMIZED EVALUATION OF VASCULAR EFFECT OF NORVASC
STUDY (PREVENT): AN ITALIAN CUSTOMIZATION
Mantovani LG1, Bustacchini S2, de Portu S1, Ruffo P2
1Universita’ degli Studi di Milano, Milan, Italy; 2Pfizer Italia S.r.l,
Rome, Italy |
|
PCV22 |
A PHARMACOECONOMIC
EVALUATION OF AGGRESSIVE LIPID-LOWERING THERAPY COMPARED WITH
ANGIOPLASTY IN STABLE CORONARY ARTERY DISEASE IN SPAIN
Domingo E1, Macaya C2, Fernandez I3, Rejas J3, Hernández G4
1Hospital Vall d'Hebron, Barcelona, Spain; 2Hospital Clinico San Carlos,
Madrid, Spain; 3Pfizer, S.A, Alcobendas, Madrid, Spain; 4Pfizer S.A,
Alcobendas, Madrid, Spain |
|
PCV23 |
PHARMACOECONOMIC
COMPARISON OF THE ANTIHYPERTENSIVE TREATMENT WITH TWO DIFFERENT
ANGIOTENSINE CONVERTING ENZYME INHIBITORS: PERINDOPRIL AND ENALAPRIL
Hermanowski T1, Jaworski R2, Czech M2, Pachocki R2
1Drugs Institute, Warsaw, Poland; 2Servier Polska, Warsaw, Poland |
|
PCV24 |
COST-EFFECTIVENSS OF
ANTICOAGULATION MANAGEMENT IN TWO MODELS OF CARE
You JH, Lai MW, Chan EM, Cheng G
The Chinese University of Hong Kong, Hong Kong, China |
|
PCV25 |
ECONOMIC EVALUATION OF
PRIMARY PREVENTION OF CVD EVENTS WITH ATORVASTATIN: AN ITALIAN
PERSPECTIVE
Mantovani LG1, Ruffo P2, Bustacchini S2, Pisani M1
1Universita’ degli Studi di Milano, Milan, Italy; 2Pfizer Italia S.r.l,
Rome, Italy |
|
PCV26 |
THE HEALTH ECONOMIC
IMPLICATIONS OF TREATING ANEMIA IN PATIENTS WITH CONGESTIVE HEART
FAILURE
Caro J1, Klittich W1, Caro G2
1Caro Research Institute, Concord, MA, USA; 2Caro Research Institute,
Dorval, QC, Canada |
|
PCV27 |
COMPARING RESOURCE USE
INTENSITY IN THREE POPULATIONS WITH ATHEROTHROMBOSIS
Migliaccio-Walle K, Ishak K, Caro J
Caro Research Institute, Concord, MA, USA |
|
PCV28 |
PERSISTENCE WITH
ANTIHYPERTENSIVE DRUG TREATMENT: AN EVALUATION BASED ON A BAYESIAN
COST-EFFECTIVENESS APPROACH
Baio G1, Degli Esposti L2, Saragoni S2, Degli Esposti E3, Capone A4,
Pammolli F1
1University of Florence, Florence, Italy; 2CliCon Srl - Health,
Economics and Outcomes Research, Ravenna, Italy, Ravenna, Italy; 3Health
Directorate, Ravenna Local Health Unit, Italy, Ravenna, Italy; 4Private
Consultant, Ravenna, NA, Italy |
|
PCV29 |
THE COST-EFFECTIVENESS
OF DIAGNOSTIC STRATEGIES WITH ANGIOGRAPHY AND/OR DUPLEX SCANNING FOR
AORTOILIAC AND FEMOROPOPLITEAL ARTERIAL DISEASE
Coffi S, Dijkgraaf M, Ubbink D, Reekers J, Legemate D
Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
|
|
PCV30 |
PROBABILISTIC
SENSITIVITY ANALYSIS FOR EVALUATING COST-EFFECTIVENESS IN SECONDARY
PREVENTION OF ISCHEMIC EVENTS
Lennes X1, Carita P2, Gabriel S2
1Cresge-Labores Lille University, Lille, France; 2Sanofi-Synthelabo,
Bagneux, France |
|
PCV31 |
ACCEPTANCE AND
RELIABILITY OF A COST-MEASUREMENT QUESTIONNAIRE IN CARDIAC
REHABILITATION
Schweikert B1, Hahmann HW2, Leidl R1
1University of Ulm, Ulm, Germany; 2Klinik Schwabenland,
Isny-Neutrauchburg, Germany |
|
PCV32 |
THE USE OF STATINS IN
SECONDARY CARE: EVIDENCE FROM ACTUAL PRACTICE DATA
Degli Esposti L1, Degli Esposti E2, Valpiani G1, Saragoni S1
1CliCon Srl - Health, Economics and Outcomes Research, Ravenna, Italy;
2Ravenna Local Health Unit, Ravenna, Italy |
|
PCV33 |
COST-EFFECTIVENESS OF
METHODS TO QUIT SMOKING IN FINNISH HEALTH CARE
Jormanainen VJ, Hahl J
GlaxoSmithKline Oy, Espoo, Finland |
|
PCV34 |
COST-EFFECTIVENESS OF
PATHOGEN INACTIVATION FOR PLATELET TRANSFUSIONS IN DUTCH CARDIAC SURGERY
Postma MJ1, de Wolf JT2, van Hulst M1, Staginnus U3, Smit Sibinga CT4
1Groningen University Institute for Drug Exploration/university of
Groningen Research Institute of Pharmacy (GUIDE/GRIP), Groningen,
Netherlands; 2University Hospital Groningen, Groningen, Netherlands;
3Baxter, S.L, Madrid, Spain; 4Sanquin, Amsterdam, Netherlands |
|
PCV35 |
COSTS OF STROKE: A
COMPARISON OF REGULAR CARE AND THREE EXPERIMENTAL STROKE SERVICES IN THE
NETHERLANDS
Van Exel J, Koopmanschap M
Erasmus University, Rotterdam, Netherlands |
|
PCV36 |
OBESITY AND POTENTIAL
COST OFFSETS FROM WEIGHT LOSS - FINDINGS FROM THE SWEDISH MALMO
PREVENTION STUDY
Persson U1, Odegaard K1, Nilsson JA2, Nilsson P2, Berglund G2
1IHE, Lund, Sweden; 2University Hospital, Malmo, Sweden |
|
Clinical Outcomes Presentations |
|
PCV37 |
DOES COMPLIANCE WITH ACE-I, DIGOXIN AND
SPIRONOLACTONE INFLUENCE THE TIME TO EVENT IN PATIENTS WITH HEART
FAILURE?
Gwadry-Sridhar F1, Arnold M2, Weaver B1, Guyatt G1
1McMaster University, London, ON, Canada; 2London Health Sciences
Centre, London, ON, Canada |
|
PCV38 |
LIPID LOWERING
MEDICATIONS FOLLOWING CORONARY REVASCULARIZATION PROCEDURES
Brophy J, Bourgault C, Brassard P
McGill University, Montreal, QC, Canada |
|
PCV39 |
A REVIEW OF THE
PHARMACOTHERAPEUTIC MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION
Richard LJ, Howard PA, Thorpe T
Heron Evidence Development LTD, Stevenage, United Kingdom |
|
PCV40 |
COMORBIDITIES CAUSING
INCREASING MORTALITY AT AGES UNDER 65 IN CARDIOVASCULAR DISEASE AND
HYPERTENSION
Farquhar IV1, Summers KH2
1Health Services Solutions, Inc, Columbia, MD, USA; 2Eli Lilly and
Company, Indianalpolis, IN, USA |
|
PCV41 |
SCREENING FOR
ANEURYSMS AFTER SUCCESSFUL TREATMENT FOR SUBARACHNOID HAEMORRHAGE: DO WE
HAVE THE EVIDENCE?
Buskens E1, Wermer M1, van der Schaaf I1, van Hout B1, Bossuyt P2,
Rinkel G1
1UMCU, Utrecht, Netherlands; 2AMC, Amsterdam, Netherlands |
|
PCV42 |
UNCERTAINTIES IN
COST-EFFECTIVENESS EVALUATION OF CAROTID ANGIOPLASTY AND STENTING
Janssen MP
University Medical Center Utrecht, Utrecht, Netherlands |
|
Quality of Life Presentations |
|
PCV43 |
IS THERE ANY
RELATIONSHIP BETWEEN COMPLIANCE AND HRQOL IN PATIENTS WITH HEART
FAILURE?
Gwadry-Sridhar F1, Weaver B1, Guyatt G1, Arnold M2
1McMaster University, London, ON, Canada; 2London Health Sciences
Centre, London, ON, Canada |
|
PCV44 |
THE IMPACT OF AN
EDUCATIONAL INTERVENTION ON MULTIPLE HEALTH REALTED QUALITY OF LIFE
MEASURES IN PATIENTS WITH HEART FAILURE (HF)
Gwadry-Sridhar F1, Guyatt G1, Weaver B1, Arnold M2
1McMaster University, London, ON, Canada; 2London Health Sciences
Centre, London, ON, Canada |
|
PCV45 |
DETERMINANTS OF
FIRST-YEAR QUALITY OF LIFE (QOL) AFTER SURGERY – INTERIM ANALYSIS OF A
RANDOMISED TRIAL WITH LAPBAND-SURGERY AND VERTICAL BANDED GASTROPLASTY (VBG)
Mastrigt van G, Dielen van F, Nieman F, Voss G, Greve J
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands |
|
PCV46 |
CORRELATES OF
SATISFACTION WITH PAIN CONTROL AMONG CARDIOVASCULAR PATIENTS IN THE US
(2001)
Wolosin RJ
Press Ganey Associates, South Bend, IN, USA |
|
PCV47 |
THE ASSESSMENT OF THE
INFLUENCE OF AN EDUCATIONAL INTERVENTION ON PATIENT IMPORTANT OUTCOMES
INCLUDING HEALTH RELATED QUALITY OF LIFE (HRQOL) AND MORTALITY USING A
TIME-TO-EVENT SURVIVAL ANALYSIS IN PATIENTS WITH HEART FAILURE
Gwadry-Sridhar F1, Weaver B1, Guyatt G1, Arnold M2
1McMaster University, London, ON, Canada; 2London Health Sciences
Centre, London, ON, Canada |
|
PCV48 |
WHAT IS THE
WILLINGNESS TO PAY FOR FUTURE HEALTH BENEFITS AMONG HYPERTENSIVE
PATIENTS – A PILOT STUDY IN POLISH SETTING.
Czech M1, Splawiński J2, Hermanowski T2, Pachocki R1, Czech M3
1Servier Polska, Warsaw, Poland; 2Drug Institute, Warsaw, Poland;
3Warsaw University of Technology, Warsaw, Poland |
|
PCV49 |
THE INFLUENCE OF
COPAYMENTS ON THE DEMAND FOR DRUGS WITH THERAPEUTIC COMPETITORS: THE
STATINS
Esposito D
University of California, Santa Barbara, Goleta, CA, USA |
|
Healthcare Policy Presentations |
|
PCV50 |
EVALUATION OF NITRATE
PRESCRIPTION PATTERNS AMONG PHYSICIANS FROM DIFFERENT SPECIALITIES IN
ISRAEL
Reuveni H, Preis M, Elhayani A, Lifshitz M, Peled R
Ben Gurion University, Beer Sheva, Israel |
|
PCV51 |
POSSIBILITIES OF NEW
TECHNOLOGIES AMONG PATIENTS WITH HYPERTENSION: FEASIBILITY AND
ACCEPTANCE OF AN EDUCATIVE INTERVENTION THROUGH SHORT MESSAGES TO THE
PATIENT’S CELLULAR PHONE
De la Figuera M1, Márquez E2, Ruilope LM3, Figueras M4, Ylla-Catalŕ A4,
Balańŕ M5, Naval J6
1ABS La Mina, Grupo Cumplimiento SEHLELHA, Barcelona, Spain; 2C.S. La
Orden, Grupo Cumplimiento SEHLELHA, Huelva, Spain; 3Hospital 12 de
Octubre. SEHLELHA, Madrid, Spain; 4Novartis Farmacéutica, S.A,
Barcelona, Spain; 5Excelent Farma, Barcelona, Spain; 6Infosciencia, S.L,
Barcelona, Spain |
|
PCV52 |
LOW LEVEL OF
CONSISTENCY BETWEEN QUALITATIVE (NCEP-II) AND QUANTITATIVE METHODS TO
RECOMMEND PHARMACEUTICAL TREATMENT OF HYPERCHOLESTEROLEMIA IN
INDIVIDUALS WITHOUT CORONARY HEART DISEASE
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain |
|
PCV53 |
INFLUENCE OF THREE
HYPERTENSION GUIDELINES ON RATES OF TREATMENT INDICATION
Rosery H1, Hense HW2
1Institute for Medical Outcome Research, Lorrach, Germany; 2University
of Muenster, Muenster, Germany |
|
PCV54 |
SMOKING CESSATION:
RELEVANCE IN THE UNDER 25 GROUP
Taďeb C1, Piergiovanni J2, Myon E1
1Programmes Pharmaco Economiques Pierre Fabre, Boulogne Billancourt,
France; 2Centre de Formation Ste Cecile, Albi, France |
|
PCV55 |
SMOKING DEPENDENCY:
AUDIT CARRIED OUT AMONG THE UNDER 25 GROUP
Taďeb C1, Piergiovanni J2, Myon E1
1Programmes Pharmaco Economiques Pierre Fabre, Boulogne Billancourt,
France; 2Centre de Formation Ste Cecile, Albi, France |
|
PCV56 |
ALLOCATION OF
RESOURCES BETWEEN SMOKING CESSATION METHODS AND PHARMACEUTICAL TREATMENT
OF HYPERCHOLESTEROLEMIA BASED ON COST-EFFECTIVENESS AND THE SOCIAL
WELFARE FUNCTION
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain |
|
PCV57 |
IMPLICATIONS OF
TREATMENT GUIDELINES: WHAT STATINS DO WE REALLY NEED?
Haiderali A1, Rocchi A2
1AstraZeneca Canada, Mississauga, ON, Canada; 2Axia Research, Hamilton,
ON, Canada |
|
PCV58 |
RANDOMIZED CONTROLLED
INTERVENTION IN CARDIOVASCULAR DRUG TREATMENT IN NURSING HOMES
Ulfvarson J1, von Bahr C1, Wredling R2
1Söder Sjukhuset, Stockholm, Sweden; 2Karolinska Institute, Stockholm,
Sweden |
| |
GASTROINTESTINAL
DISEASES/DISORDERS |
|
Economic Outcomes Presentations |
|
PGS1 |
EMPLOYMENT LOSSES
RELATED TO INFLAMMATORY BOWEL DISEASE IN THE UNITED STATES: RESULTS FROM
THE NATIONAL INTERVIEW SURVEY
Longobardi T1, Jacobs P2, Bernstein CN1
1University of Manitoba, Winnipeg, Manitoba, Canada; 2Institute of
Health Economics, Edmonton, Alberta, Canada |
|
PGS2 |
ECONOMIC BURDEN OF IBS
Badia X1, Mearín F2, Caballero AM3, Díaz-Rubio M4, Domínguez E4,
Garrigues V5, Pique J6, Cucala M7, Espinosa C7, Balańŕ M7, Roset M1
1Health Outcomes Research Europe, Barcelona, Spain; 2Centro Médico
Teknon, Barcelona, Spain; 3Universidad de Granada, Granada, Spain;
4Hospital Clínico San Carlos, Madrid, Spain; 5Hospital la Fé, Valencia,
Spain; 6Hospital Clínic, Barcelona, Spain; 7Novartis Farmacéutica,
Barcelona, Spain |
|
PGS3 |
HEALTH CARE RESOURCE
UTILIZATION AND COSTS OF TREATING NSAID-ASSOCIATED GASTROINTESTINAL
TOXICITY IN JAPAN: FEASIBILITY OF A DELPHI-PANEL APPROACH IN JAPAN
Kamae I1, Yanagisawa S1, Aino H1, Niimi S2
1Kobe University, Kobe, Japan; 2Social Survey Research Information Co.,
Ltd, Tokyo, Japan |
|
PGS4 |
LOW-DOSE PPI AND
STANDARD-DOSE PPI COMPARED WITH H2RA FOR MAINTENANCE THERAPY OF GERD – A
COST-EFFECTIVENESS ANALYSIS USING MARKOV MODEL
You JH, Lee AC, Wong SC, Chan FK
The Chinese University of Hong Kong, Hong Kong, China |
|
PGS5 |
A COST-EFFECTIVENESS
ANALYSIS OF ESOMEPRAZOLE VS. OMEPRAZOLE IN THE ACUTE TREATMENT OF
PATIENTS WITH REFLUX OESOPHAGITIS IN GREECE
Christodoulopoulou A1, Karokis A1, Wahlqvist P2
1AstraZeneca SA, Athens, Greece; 2AstraZeneca R&D Mölndal, Mölndal,
Sweden |
|
PGS6 |
COST COMPARISON OF
ESOMEPRAZOLE BASED AND OMEPRAZOLE BASED HELICOBACTER PYLORI ERADICATION
STRATEGIES IN DUODENAL ULCER DISEASE IN GREECE
Christodoulopoulou A1, Karokis A1, Wahlqvist P2
1AstraZeneca SA, Athens, Greece; 2AstraZeneca R&D Mölndal, Mölndal,
Sweden |
|
PGS7 |
ANALYSIS OF RESOURCE
USE AND COSTS ASSOCIATED WITH MINOR NON-STEROIDAL ANTI-INFLAMMATORY
DRUGS (NSAID) RELATED GASTRO-INTESTINAL (GI) EVENTS
Annemans L1, Vanoverbeke N2
1Ghent University/HEDM, Meise, Belgium; 2HEDM, Meise, Belgium |
|
Clinical Outcomes Presentations |
|
PGS8 |
META-ANALYSIS OF
ESOMEPRAZOLE 40MG AND LANSOPRAZOLE 30MG IN THE HEALING OF REFLUX
OESOPHAGITIS
Edwards S
AstraZeneca UK Ltd, Luton, Bedfordshire, United Kingdom |
|
PGS9 |
OUTCOMES ANALYSIS OF
RABEPRAZOLE (ACIPHEX) USE AT A VETERAN AFFAIRS MEDICAL CENTER
Gordon M
McGuire Veterans Affairs Medical Center, Richmond, VA, USA |
|
PGS10 |
TOWARDS A MULTISTAGE
DECISION ANALYSIS FOR THE TREATMENT OF FAECAL INCONTINENCE
Dijkgraaf M1, Deutekom M1, Bossuyt P1, Terra M1, Dobben A1, Berghmans
L2, Stoker J1
1Academic Medical Center, University of Amsterdam, Amsterdam,
Netherlands; 2University Hospital Maastricht, Maastricht, Netherlands
|
|
Quality of
Life/Utility/Preference/Productivity Presentations |
|
PGS11 |
IMPACT OF IBS ON
QUALITY OF LIFE AND PSYCHOLOGICAL WELL-BEING IN PATIENTS AND RELATIVES
Badia X1, Mearín F2, Pique J3, Garrigues V4, Domínguez E5, Díaz-Rubio
M5, Caballero AM6, Cucala M7, Espinosa C7, Balańŕ M7, Roset M1
1Health Outcomes Research Europe, Barcelona, Spain; 2Centro Médico
Teknon, Barcelona, Spain; 3Hospital Clínic, Barcelona, Spain; 4Hospital
la Fé, Valencia, Spain; 5Hospital Clínico San Carlos, Madrid, Spain;
6Universidad de Granada, Granada, Spain; 7Novartis Farmacéutica,
Barcelona, Spain |
|
PGS12 |
IRRITABLE BOWEL
SYNDROME (IBS) SIGNIFICANTLY AFFECTS PATIENT QUALITY OF LIFE (QOL) AND
IS RESPONSIBLE FOR HIGH COSTS IN FRANCE: THE ENCOLI STUDY
Brun-Strang C1, Lafuma A2, Dapoigny M3, Wainsten JP4
1Novartis-Pharma, Rueil-Malmaison, France; 2CEMKA-EVAL, Bourg La Reine,
France; 3Hotel Dieu, Clermont-Ferrand, France; 4Université Paris XII,
Paris, France |
|
PGS13 |
HEALTH STATE UTILITIES
AND WILLINGNESS TO PAY IN GERD PATIENTS WITH HEARTBURN
Kartman B
AstraZeneca R&D Mölndal, Mölndal, Sweden |
|
PGS14 |
CORRELATION BETWEEN
DIFFERENT PRODUCTIVITY VARIABLES OBTAINED FROM THE WPAI-GERD
QUESTIONNAIRE
Wahlqvist P, Carlsson J
AstraZeneca R&D Mölndal, Mölndal, Sweden |
|
Health Policy Presentations |
|
PGS15 |
FORMULARY CONVERSION
OF PROTON PUMP INHIBITORS: MONITORING FOR POTENTIAL DRUG INTERACTION
DeLattre ML, Le GH, Schaefer MG, Morreale A, Plowman B
VA San Diego Healthcare System, San Diego, CA, USA |
|
PGS16 |
EVALUATION OF THE USE
OF PROTON PUMP INHIBITORS IN A PUBLIC HOSPITAL IN HONG KONG
Lee VW1, Yick PK2, Yung G1, Tam KY1
1The Chinese University of Hong Kong, Shatin, Hong Kong; 2Pamela Youde
Nethersole Eastern Hospital, Hong Kong |
| |
NEUROLOGICAL
DISEASES/DISORDERS & PAIN
(Including Dementia, Alzheimer’s Disease, Headache, Migraine, Pain,
Epilepsy, Seizures, and Multiple Sclerosis) |
|
Healthcare Policy Presentations |
|
PNP1 |
CHOLINESTERASE INHIBITORS
REDUCE INSTITUTIONALIZATION RISK AND MAY REDUCE OVERALL ECONOMIC BURDEN
FOR PATIENTS WITH DEMENTIA IN A NATURALISTIC TREATMENT SETTING
Luong D1, Sambrook R2, Yu A2, COSID
Investigators3
1Janssen Ortho Inc, Toronto, ON, Canada; 2Syreon Corporation, Vancouver,
BC, Canada; 3Canada |
|
PNP2 |
ECONOMIC IMPACT OF
TREATMENT OF DEMENTIA FOR GERMANY – A PROGNOSIS TO 2050
Happich MV1, Hallauer J2
1Technical University, Berlin, Germany; 2Charité, University Hospital,
Berlin, Germany |
|
PNP3 |
SOCIO-ECONOMIC IMPACT
OF CHRONIC DAILY HEADACHE IN THE GENERAL POPULATION IN FRANCE
Lantéri-Minet M1, Auray JP2, Chazot G3, Dartigues JF4, Duru G5, Henry
P6, Lucas C7, Pradalier A8, el Hasnaoui A9, Gaudin AF9
1Hospital Pasteur, Nice, France; 2Université Lyon, Villeurbanne, France;
3Hopital Cardio |
|
PNP4 |
SWITCHING AND
PERSISTENCY IN A NSAID AND COX-2 SPECIFIC INHIBITOR USER POPULATION IN
MANAGED CARE
Harley C1, Wagner S2, Nelson M1
1Ingenix, Eden Prairie, MN, USA; 2Pharmacia Corporation, Peapack, NJ,
USA |
|
PNP5 |
DIRECT COSTS OF BACK
PAIN IN THE UNITED STATES: A NATIONAL ESTIMATE
Mychaskiw MA, Thomas III J
Purdue University, West Lafayette, IN, USA |
|
PNP6 |
THE BURDEN OF
MIGRAINE: BEYOND DIRECT HEALTH CARE COSTS
Badia X, Magaz S, Gutiérrez L
Health Outcomes Research Europe, Barcelona, Spain |
|
PNP7 |
ECONOMIC EVALUATION OF
LEVETIRACETAM AS ADJUNCTIVE THERAPY IN REFRACTORY EPILEPTIC PATIENTS
Blais L1, Sheehy O1, St-Hilaire JM1, Bernier JP1, Godfroid P2, Le Lorier
J1
1Centre de Recherches, CHUM, Montreal, QC, Canada; 2UCB Pharma, Outcomes
Research Unit, R&D, Braine l'Alleud, Belgium |
|
PNP8 |
ADJUNCTIVE TOPIRAMATE
THERAPY IN PATIENTS WITH REFRACTORY SEIZURES: A LIFETIME COST-UTILITY
ANALYSIS
Maltoni S, Messori A
Careggi Hospital, Florence, Italy |
|
PNP9 |
RETROSPECTIVE
EVALUATION OF DYSPORT™ AND BOTOX™ DRUG UTILIZATION IN THE MANAGEMENT OF
PATIENTS WITH CERVICAL DYSTONIA OR BLEPHAROSPASM
Magar R1, Marchetti A1, Ahmed F2, Ferguson I3
1Thomson Physicians World, Secaucus, NJ, USA; 2Hull Royal Infirmary,
Hull, United Kingdom; 3Frenchay Hospital, Bristol, United Kingdom |
|
PNP10 |
ECONOMIC IMPACT OF
GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS
Ollendorf DA1, Jilinskaia E1, Oleen-Burkey M2
1PharMetrics Inc, Watertown, MA, USA; 2Teva Neuroscience, Kansas City,
MO, USA |
|
Quality of Life Presentations |
|
PNP11 |
USE OF THE TOPS AS A
PAIN-SPECIFIC HRQOL INSTRUMENT
Oderda GM, Lipman AG, Ashburn MA, Stockdale W
University of Utah, Salt Lake City, UT, USA |
|
PNP12 |
PHYSICIAN PREFERENCE
FOR ANTIEPILEPTIC DRUG CONCENTRATION TESTING
Baumann RJ, Ryan M, Yellowitz AS
University of Kentucky, Lexington, KY, USA |
|
PNP13 |
QUALITY OF LIFE (QOL)
AND PHARMACOECONOMICAL ASPECTS IN PATIENTS WITH SYMPTOMATIC
LOCALIZATION-RELATED EPILEPSIES (SLE) IN MOSCOW
Guekht AB1, Gusev EI1, Belousov JB1, Bykov AV2, Dzugaeva FK1, Milchakova
LE1, Mitrokhina TV1
1Russian State Medical University, Moscow, Russia; 2Russian Society for
Pharmacoeconomics Research, Moscow, Russia |
|
PNP14 |
WITHDRAWN |
|
PNP15 |
EVALUATION OF THE
RELATIONSHIP BETWEEN EPILEPSY SEVERITY AND UTILITY
Selai C1, Kaiser S2, Trimble M1, Price M3
1UCL Institute of Neurology, London, Middlesex, United Kingdom;
2University of Heidelberg, Heidelberg, Germany; 3Janssen-Cilag, High
Wycombe, Bucks, United Kingdom |
|
Healthcare Policy Presentations |
|
PNP16 |
MEDICATION USE IN
PATIENTS WITH LOW BACK PAIN: DATA FROM MANAGED CARE
Harley C1, Wagner S2, Nelson M1
1Ingenix, Eden Prairie, MN, USA; 2Pharmacia Corporation, Peapack, NJ,
USA |
|
PNP17 |
COMPLIANCE OF TWO
TREATMENTS OF ALZHEIMER'S DISEASE
Barbeau M, Baladi JF
Novartis Pharma Canada Inc, Dorval, QC, Canada |
|
PNP18 |
FORMULARY DECISION
SUPPORT FOR INTERFERON-BETA-1A USING ANALYSIS OF CARE-SEEKING BEHAVIOR
FOR MULTIPLE SCLEROSIS
Meyer C1, Phipps R2, Cooper D1, Neff S1, Wright A1
1AdvancePCS, Hunt Valley, MD, USA; 2Serono, Inc, Rockland, MA, USA
|
| |
MENTAL HEALTH |
|
Economic Outcomes Presentations |
|
PMH1 |
THE HEALTH CARE COSTS
OF SCHIZOPHRENIA IN AUSTRALIA: 18-MONTH FOLLOW-UP RESULTS
Christova L1, Davey P1, Jackson D1, Montgomery W2, deCastella A3,
Fitzgerald P3, Brewer K3, Filia K3, Collins J3, Kulkarni J3
1Medical Technology Assessment Group, Chatswood West, NSW, Australia;
2Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 3Dandenong
Hospital Dept of Psychiatry, Dandenong, VIC, Australia |
|
PMH2 |
ANTIPSYCHOTIC USE
PATTERNS AND HEALTHCARE COSTS FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED
WITH HALOPERIDOL, OLANZAPINE OR RISPERIDONE IN A MEDICAID POPULATION
Ramsey JL1, Hutchins D2, Zhu B1, Zhao Z1, Gibson PJ1, Lothgren M3
1Eli Lilly and Company, Indianapolis, IN, USA; 2Advance PCS, Scottsdale,
AZ, USA; 3Eli Lilly and Company, Windelsham, Surrey, United Kingdom
|
|
PMH3 |
A COST-EFFECTIVENESS
COMPARISON OF OLANZAPINE AND RISPERIDONE IN THE TREATMENT OF
SCHIZOPHRENIA IN ITALY
Beard S1, Lothgren M2, Giudi L3, Ramacciotti F4, Nardini M5, Berardi D6
1RTI Health Solutions, Manchester, United Kingdom; 2Eli Lilly & Company
Ltd, Windlesham, United Kingdom; 3Eli Lilly Italia S.P.A, Florence,
Italy; 4Centro di Igene Mentale di Palazzo Boldu, Venezia, Italy;
5Policlinico di Bari, Bari, Italy; 6Instituto di Psichiatrica, Bologna,
Italy |
|
PMH4 |
ESTIMATING MEDICAL
COST REDUCTION IN TREATING SCHIZOPHRENIA WITH CLOZAPINE
Sendersky V
Duke University/Novartis Pharmaceuticals Corporation, East Hanover, NJ,
USA |
|
PMH5 |
A DISCRETE EVENTS
MODEL OF LONG-TERM OUTCOMES AND COST OF TREATMENT WITH LONG ACTING
RISPERIDONE IN SCHIZOPHRENIA
Heeg BM1, van Aalst G2, van den Arend IJ3, Mehnert A4, van Hout B1
1PharMerit BV, Capelle a/d IJssel, Netherlands; 2Mentrum Mental Health,
Amsterdam, Netherlands; 3Janssen-Cilag Nederland BV, Tilburg,
Netherlands; 4Janssen Pharmaceutica NV, Beerse, Belgium |
|
PMH6 |
DIRECT MEDICAL COSTS
FOR TREATMENT OF PATIENTS EXPERIENCING BIPOLAR DISORDER EPISODES IN THE
UK
Finnern HW1, Lothgren M1, Gandhi G2
1Eli Lilly & Company Ltd, Windlesham, United Kingdom; 2Lilly Research
Centre, Windlesham, UK |
|
PMH7 |
BOTTOM-UP OR TOP-DOWN?
IMPACT OF PATIENT SELECTION ON COST-OF-ILLNESS RESULTS
van Asselt ADI1, Dirksen CD1, Severens JL2, Arntz A2
1University Hospital Maastricht, Maastricht, Netherlands; 2University
Maastricht, Maastricht, Netherlands |
|
PMH8 |
COST-EFFECTIVENESS OF
MIRTAZAPINE COMPARED TO FLUOXETINE IN THE TREATMENT OF MODERATE AND
SEVERE DEPRESSION IN HUNGARY
Van Loon J1, Horvath LZ2, Faludi G3
1Mapi Values Netherlands, Houten, Netherlands; 2Organon Hungary,
Budapest, Hungary; 3Semmelweis Medical University, Kútvölgyi Hospital,
Budapest, Hungary |
|
PMH9 |
ESTIMATING
COST-EFFECTIVENESS OF CONCERTA OROS IN ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER (ADHD) – ADAPTING THE CANADIAN COORDINATING OFFICE FOR HEALTH
TECHNOLOGY ASSESSMENT’S (CCOHTA) ECONOMIC MODEL OF METHYLPHENIDATE
IMMEDIATE RELEASE VERSUS BEHAVIOURAL INTERVENTIONS FROM A PARENT’S
PERSPECTIVE
Annemans L1, Ingham M2
1HEDM, Meise, Belgium; 2Janssen Pharmaceutica, Beerse, Belgium |
|
PMH10 |
LENGTH OF STAY AND
ANTIPSYCHOTIC TREATMENT COSTS OF PATIENTS WITH ACUTE PSYCHOSIS ADMITTED
TO HOSPITAL: DESCRIPTION AND ASSOCIATED FACTORS – THE PSYCHOSP STUDY
Peiró S1, Gómez G2, Navarro M3, Guadarrama I4, Rejas J5
1Fundación Instituto de Investigación en Servicios de Salud, Escuela
Valenciana de Estudios para la Salud, Valencia, Spain; 2Fundación
Instituto de Investigación en Servicios de Salud, Valencia, Spain;
3Servicio de Farmacia, Hospital de Santa Maria, Lleida, Spain; 4División
Corporativa e Institucional, Pfizer SA, Alcobendas, Madrid, Spain;
5Pfizer, S.A, Alcobendas, Madrid, Spain |
|
Clinical Outcomes Presentations |
|
PMH11 |
ANTIPSYCHOTIC
MEDICATION PATTERNS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED
WITH OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO
OBSERVATIONAL STUDY
Eichmann F1, Reitberger U1, Spannheimer A1, Lothgren M2, Clouth J3,
Naber D4
1Kendle International Inc, Munich, Germany; 2Eli Lilly & Company Ltd,
Windlesham, United Kingdom; 3Lilly Deutschland, Bad Hamburg, Germany;
4Universitäts-Krankenhaus Eppendorf, Hamburg, Germany |
|
PMH12 |
PATIENT AND DISEASE
CHARACTERISTICS IN SCHIZOPHRENIA OUTPATIENTS AND INPATIENTS TREATED WITH
OLANZAPINE AND HALOPERIDOL IN GERMANY: RESULTS FROM THE GEO
OBSERVATIONAL STUDY
Eichmann F1, Reitberger U1, Spannheimer A1, Lothgren M2, Clouth J3,
Naber D4
1Kendle International Inc, Munich, Germany; 2Eli Lilly & Company Ltd,
Windlesham, United Kingdom; 3Lilly Deutschland GmbH, Bad Hamburg,
Germany; 4Universitäts-Krankenhaus Eppendorf, Hamburg, Germany |
|
PMH13 |
STUDY DESCRIPTION AND
BASELINE RESULTS OF THE SCHIZOPHRENIA OUTCOMES SURVEY (SOS)
OBSERVATIONAL STUDY IN BELGIUM
Annemans L1, Moeremans K2, Peuskens J3, Gillain B4, De Graeve D5, Albert
A6, Deberdt W7, Lothgren M8, Gilis P9
1Ghent University, HEDM, Meise, Belgium; 2HEDM, Meise, Belgium;
3Universitair Centrum St Jozef, Kortenberg, Belgium; 4Cliniques
Universitaires St Luc, Brussels, Belgium; 5University of Antwerp,
Antwerpen, Belgium; 6Université de Ličge, Liege, Belgium; 7Eli Lilly,
Brussels, Belgium; 8Eli Lilly and Company, Windelsham, Surrey, United
Kingdom; 9Eli Lilly Benelux s.a, Brussels, Belgium |
|
PMH14 |
INCIDENCE OF
HYPERLIPIDEMIA DURING TREATMENT OF
SCHIZOPHRENIA: FINDINGS IN A CLAIMS DATABASE
Zhao Z1, Ascher-Svanum H1, Baker RW2, Cavazzoni P2
1Eli Lilly and Company, Indianapolis, IN, USA; 2Lilly Research
Laboratories, Indianapolis, IN, USA |
|
PMH15 |
SEXUAL DYSFUNCTION AND
ANTIPSYCHOTIC DRUG ADHERENCE IN PEOPLE WITH SCHIZOPHRENIA
Weiden PJ1, Mackell J2, McDonnell DD3
1SUNY Health Sciences Center at Brooklyn, Brooklyn, NY, USA; 2Pfizer,
Inc, New York, NY, USA; 3Consumer Health Sciences, Princeton, NJ, USA
|
|
PMH16 |
RECRUITMENT FOR
SCHIZOPHRENIA RESEARCH: EXPLORING THE DIFFERENCES BETWEEN COMMUNITY
MENTAL HEALTH CENTERS AND NATIONAL ALLIANCE FOR THE MENTALLY ILL
Mackell J1, McDonnell DD2
1Pfizer, Inc, New York, NY, USA; 2Consumer Health Sciences, Princeton,
NJ, USA |
|
PMH17 |
TREATMENT SATISFACTION
AND COMPLIANCE WITH RISPERIDONE USE IN PATIENTS WITH BIPOLAR DISORDER
Bolge SC1, Meletiche D2, Lasser R2
1Consumer Health Sciences, Princeton, NJ, USA; 2Janssen Pharmaceutica,
Titusville, NJ, USA |
|
PMH18 |
EVALUATION OF CLINICAL
EFFICACY OF WEEKLY FLUOXETIN COMPARED WITH DAILY FLUOXETIN 40 MG IN
AMBULATORY PATIENTS WITH MAJOR DEPRESSION
Ortega T1, Karki SD2, Bellnier T2
1Geriatric Pharamcotherapy Institute Inc, Pittsford, NY, USA; 2School of
Pharmacy, SUNY at Buffalo, Rochester, NY, USA |
|
PMH19 |
GENDER DIFFERENCES IN
PSYCHOACTIVE MEDICATION TREATMENT FOR ATTENTION-DEFICIT/HYPERACTIVITY
DISORDER(AD/HD): RESULTS FROM A POPULATION-BASED STUDY
Barbaresi WJ1, Katusic SK1, Colligan RC1, Weaver AL1, Pankratz VS1,
Mrazek DA1, Hankin CS2, Jacobsen SJ1
1Mayo Clinic, Rochester, MN, USA; 2McNeil Consumer and Specialty
Pharmaceuticals, Mountain View, CA, USA |
|
PMH20 |
THE EFFECTS OF
ETHNICITY AND ANTIPSYCHOTIC AGENT ON MEDICATION ADHERENCE IN A MEDICAID
POPULATION
Opolka J1, Rascati K1, Brown C1, Gibson P2
1The University of Texas, Austin, TX, USA; 2Eli Lilly & Co,
Indianapolis, IN, USA |
|
Quality of Life Presentations |
|
PMH21 |
IMPROVING THE
MEASUREMENT PROPERTIES OF THE QUALITY OF LIFE IN DEPRESSION SCALE
McKenna SP, Whalley D, Doward LC
Galen Research, Manchester, UK |
|
Healthcare Policy Presentations |
|
PMH22 |
ADHD HAS A SIGNIFICANT
BURDEN UPON THE INDIVIDUAL, FAMILY AND SOCIETY IN EUROPE
Ralston SJ1, Remak E2
1Eli Lilly and Company, Windlesham, Surrey, United Kingdom; 2MEDTAP
International, London, UK |
|
PMH23 |
ATTENTION DEFICIT
HYPERACTIVITY DISORDER (ADHD): A RECOGNISED DISORDER FOR CHILDREN IN
EUROPE
Ralston SR1, Gregor KJ1, Engelfriet P2
1Eli Lilly and Company, Windlesham, Surrey, United Kingdom; 2MEDTAP
International Inc, Utrecht, Netherlands |
|
PMH24 |
THERE ARE SIGNIFICANT
BARRIERS TO THE DIAGNOSIS AND TREATMENT OF ADHD IN EUROPE.
Ralston SJ1, Nuijten M2
1Eli Lilly and Company, Windlesham, Surrey, United Kingdom; 2MEDTAP
International, Jisp, Netherlands |
|
PMH25 |
CORRESPONDENCE COURSE
FOR GPS IMPROVED QUALITY AND PERSISTENCY OF ANTI-DEPRESSIVE THERAPY
(RESULTS FROM THE IMPROVE-D STUDY)
Michalek HE1, Juergens T2, Koenig A2, Landen H2, Mast O2, Stauch K2
1Physician for Neurology, Psychiatry and Psychotherapy, Hausach,
Germany; 2Bayer Vital GmbH, Leverkusen, Germany |
|
Methodology Issues Presentations |
|
PMH26 |
SIMULATING THE COURSE
OF SCHIZOPHRENIA USING DISCRETE EVENTS MODELLING
Heeg BM1, van Aalst GD2, Mehnert A3, van Hout B1
1PharMerit BV, Capelle a/d IJssel, Netherlands; 2Mentrum Mental Health,
Amsterdam, Netherlands; 3Janssen Pharmaceutica NV, Beerse, Belgium
|
| |
RESPIRATORY
DISEASES/DISORDERS |
|
Economic Outcomes Presentations |
|
PRP1 |
INPATIENT AND
OBSERVATION UNIT COSTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
O'Brien JA, Patrick AR, Duran P, Caro JJ
Caro Research Institute, Concord, MA, USA |
|
PRP2 |
STUDY TO EVALUATE
HOSPITAL COSTS FOR ACUTE EXACERBATION IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE IN SPAIN (EPOC-COST STUDY)
García A1, Fernandez I2, Rejas J2, De-Miguel G3
1Carlos Haya Hospital, Malaga, Spain; 2Pfizer, S.A, Alcobendas, Madrid,
Spain; 3Boehringer Ingelheim, San Cugat del Valles, Barcelona, Spain
|
|
PRP3 |
AN ANALYSIS OF THE
LENGTH AND COSTS OF RESPIRATOR USE WITH OBSERVATIONAL DATA BASED ON
MEDICAL RECORDS
Watanabe R1, Ohkusa Y2
1Kyoto University, Kyoto, Japan; 2Osaka University, Ibaragi, Osaka,
Japan |
|
Clinical Outcomes Presentations |
|
PRP4 |
INHALED
ANTIINFLAMMATORY MEDICATION USE AND SUBSEQUENT HOSPITALIZATIONS AMONG
TEXAS MEDICAID PATIENTS WITH PERSISTENT ASTHMA
Smith M, Rascati K
The University of Texas, Austin, TX, USA |
|
PRP5 |
EPIDEMIOLOGICAL STUDY
ESTIMATING THE PREVALENCE OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF
CHRONIC SINUSITIS IN GERMANY
Elies W1, Thate-Waschke IM2, Bestehorn M3, König A2, Evers T2
1Staedtische Krankenanstalten Bielefeld, Bielefeld, Germany; 2Bayer
Vital GmbH, Leverkusen, Germany; 3TNS EMNID, Pullach, Germany |
|
Quality of Life Presentations |
|
PRP6 |
ASSESSMENT OF
RESPIRATORY DISEASE SEVERITY USING POSTAL QUESTIONNAIRES
Hazell ML, Frank TL, Frank PI
North West Lung Research Centre, Manchester, UK |
|
PRP7 |
HEALTH RELATED QUALITY
OF LIFE (HRQOL) IN ASTHMA PATIENTS IN RELATIONSHIP TO ASTHMA SEVERITY
DEGREE
Rebollo P1, Ferrer M1, Serra-Batlles J2, Plaza V3, Morejon E4, Alonso J1
1Institut Municipal d´Investigació Mčdica (IMIM-IMAS); Hospital Central
de Asturias, Barcelona, Spain; 2Hospital General de Vic, Barcelona,
Spain; 3Hospital de Sant Pau, Barcelona, Spain; 4GlaxoSmithKline Espańa,
Madrid, Spain |
|
PRP8 |
QUALITY OF LIFE AND
COSTS FOR MODERATE AND SEVERE ASTHMA IN FRANCE
Lafuma A1, Brun-Strang C2, Leynadier F3, Grimfeld A4, Everhard F5
1CEMKA-EVAL, Bourg La Reine, France; 2Novartis-Pharma, Rueil-Malmaison,
France; 3Hôpital Tenon, Paris, France; 4Hôpital Trousseau, Paris,
France; 5Novartis Pharmaceuticals AG, Basel, Switzerland |
|
Healthcare Policy Presentations |
|
PRP9 |
EVALUATION OF A
DISEASE MANAGEMENT PROGRAM (DMP) FOR CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD) IN GERMANY: PRELIMINARY ASSESSMENT OF EFFECTIVENESS OF
COMPOUNDS
Lorenz J1, Gillissen A2, Möller M3, Hartung HC4, Halbach E4, Eschweiler
B5, Lindackers A5, Thate-Waschke IM6
1Gener |
|
PRP10 |
A DISEASE MANAGEMENT
PROGRAM IN FRANCE: LESSONS FROM THE RESALIS EXPERIMENT 18 MONTHS BEFORE
AND 12 MONTHS AFTER PUBLIC HEALTH INTERVENTIONS
Launois R1, Mčgnigbęto AC2, Perez V3, Roy M3, Camus A4, Gailhardou M5,
Lançon F5, Quéniart M5
1Rees, France (Réseau d'Evaluation en Economie de la Santé) Paris
(France), Paris, France; 2Rees, France, Paris, France; 3Cpam de l'eure,
Evreux, France; 4Medical Cabinet, Beaumont-le-Roger, France; 5Alliance
Medica (GSK), Marly Le Roi, France |
|
